tbuckley/cabot-search huggingface dataset:
SP0059 Eular`s patient research partner network – patients’ future involvement in research
Authors: C. Zabalan
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Research in the field of RMDs, particularly in Europe, has advanced significantly the last years. In particular, <b>the interest in developing Patient Reported Outcomes (PROs) and forms of participatory research has grown</b>. In the field of rheumatology there have been undertaken many initiatives to explore and implement participatory research. Substantial unmet needs in the area of research, highlighted in the <b>RheumaMap</b> (developed by EULAR), will however require an altogether <b>higher level of commitment and innovation</b>. Implementation of the distinct elements contained in RheumaMap will rely on scientists, patients and health professionals. In this regard EULAR PARE has developed <b>recommendations for patient-researcher collaboration</b> and also established a network of <b>40 trained patient research partners</b> of whom 6 have also graduated for the EUPATI training course. Last year it was created a <b>platform</b> (under the name of <b>Study Group for Participatory Research)</b> for knowledge exchange regarding patient participation in rheumatology care and research with the aim of establishing a group of researchers and patient research partners with an interest in developing innovative methods to elicit the voice of patients in rheumatology research, to stimulate the dialogue about the rationale, principles and conditions for patient involvement in research and to discuss and develop the nomenclature and methodology of evaluating the process, results and impact of patient participation in research and health care innovation. <b>The Learning Objectives</b> of the session are as follows: To learn from best practices of patient engagement in different disease areas To explore patient involvement in guideline development and health care innovations To explore how to evaluate patient involvement To explore how to cease the moment, how to have fun in the process <h3>Disclosure of Interest</h3> None declared
Clinical trial and ‘real-world’ data support switching from a bio-originator to its biosimilar
Authors: Jonathan Kay, Thomas Dörner, Paul Emery, Tore K Kvien, Ferdinand C Breedveld
Journal: Annals of the Rheumatic Diseases (2019)

In their correspondence, Cantini and Benucci1 voice concern regarding the recommendation of our international multidisciplinary task force on biosimilars that ‘a single switch from a bio-originator to one of its biosimilars is safe and effective.’2 This recommendation was based on consistent evidence from randomised controlled trials comparing biosimilars to their respective reference products in patients with rheumatologic diseases, in which subjects treated with a reference product were subsequently transitioned to treatment with its biosimilar. In all such studies that have been published to date, there has been no significant loss of efficacy or increase in the incidence of adverse events or of antidrug antibodies following such a change. This has been demonstrated not only for biosimilars of infliximab3–6 and etanercept,7 but also for biosimilars of adalimumab.8 9 

The NOR-SWITCH study met its primary endpoint at 52 weeks, thereby demonstrating non-inferiority of changing treatment from bio-originator infliximab to biosimilar infliximab CT-P13 (infliximab-dyyb) to continued treatment with bio-originator infliximab in patients with any of the six inflammatory diseases for which infliximab is indicated who had exhibited stable disease activity over the previous 6 months.10 It is important to recognise that this prospective, double-blind, randomised controlled trial was powered to demonstrate non-inferiority of changing to the biosimilar to continued treatment with the bio-originator in the aggregated population of patients with the six inflammatory diseases; it was not designed to assess non-inferiority of this treatment strategy in any individual disease. As Cantini and Benucci point out, 248 (51.6%) of the 481 subjects enrolled in NOR-SWITCH had inflammatory …
SAT0323 Adverse drug reactionsrelated to disease-modifying drugs (DMARD) in psoriatic arthritis patients in daily clinical practice
Authors: D. Freites Nuñez, Z. Rosales, L. León, J. Font, P. Lois, C. Vadillo, E. Pato, B. Fernández, L. Rodríguez-Rodríguez, J.A. Jover, L. Abasalo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Psoriatic arthritis (PsA) benefits from DMARDs and to know more about the adverse drug reactions (ADRs) represent an advance for the management and safety of these patients in clinical practice. <h3>Objectives</h3> To evaluate the discontinuation due to ADRs of DMARDs used in PsA patients and to analyse the possible associated factors. <h3>Methods</h3> Retrospective longitudinal observational study. Subjects: inception cohort of patients from January 2010 to ,December 2014 and followed up to December 2016, diagnosed with PsA according to ICD-10code. Main outcome: discontinuation of conventional synthetic DMARDs (csDMARDs) and biological originator DMARDs (boDMARDS) due to ADR (moderate: drug suspension regardless of the repercussions, severe: hospital admission required or death). Covariables: sociodemographic and clinical. Statistical analysis: To estimate DMARDs discontinuation rates, survival techniques were used, expressing the incidence rate (IR) per 100patients*year with their respective CI at 95%. Multivariate Cox regression models were performed to analyse the factors associated with DMARDs discontinuation due to ADRs and results were expressed in Hazard ratio(HR) and 95% CI. <h3>Results</h3> 191 patients were included, with a follow-up of 379.70 Patients*year. 50.3% were male, mean age at diagnosis was 50±14.6 years old. 46.6% of the patients had a history of cutaneous psoriasis. HLA-B27 was positive in 20% of patients. Throughout the follow-up, all patients received csDMARDs and 23 used boDMARDs. Methotrexate(MTX) was the most used drug 69.7%. 30% were on combination therapy, the most frequent was antiTNF +MTX. There were 44 discontinuations due to ADRs, IR 11.59 [8.62–15.57] and 3 were severe, requiring hospital admission (two infections and one cancer), no deaths were recorded. Among the most frequent causes of discontinuation related to ADRs were digestive intolerance 32%, nonspecific manifestations 11%, infections 9% and abnormal transaminase levels 9%. Table1 shows the DMARDs discontinuation rates due to ADRs. In the final discontinuation model related with ADRs (Table2), we observed that distress, high disease activity, corticosteroids at diagnosis and combination therapy were associated with a higher rate of discontinuation. <h3>Conclusions</h3> The discontinuation rate due to ADRs was 11.59, although most of them did not have an important clinical impact. We have found some psychological, clinical and treatment factors that can modify the DMARDs survival on PsA patients. We also observed that MTX, seems to be safe in the treatment of PsA, presenting the lowest probability of suspension related to ADRs compared with the rest of treatments. <h3>Disclosure of Interest</h3> None declared
Abstract 17740: Effects of High Intensity Interval Training on Blood Pressure and Endothelial Function in Prehypertensive and Hypertensive Patients
Authors: Jung Ho Heo, Eun-Ah Jo, Kyunng-Im Cho, Ga-in Yu
Journal: Circulation (2015)

Introduction: Recently, several studies have shown that high-intensity interval training (HIT) is superior to continuous moderate-intensity exercise (CME) for improvement on endothelial in patients with cardiovascular disease. However, little is known about its effects on changes in blood pressure, especially in hypertensive patients. Hypothesis: To compare the effects of HIT and CME on changes in blood pressure reduction and endothelial function in pre- and hypertensive patients.. Methods: Seventeen pre- and hypertensive patients, aged 52.1±7.6, participated in this study, tapered off their medications, if necessary, and were randomized to either HIT (n=9) or CME (n=8) group. HIT was composed of 5 sets of 3 min exercise at 80% HRR, and each interval was separated by 3 min recovery at 40% HRR. CME was composed of 35 min exercise at 60% HRR. Both groups were designed to use same energy expenditure, and performed exercise 5 days per week for 4 weeks. Endothelial function was determined by assessing endothelial progenitor cells (EPCs) using flow cytometry and flow mediated dilation (FMD) using ultrasonography. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at rest and during exercise at 60% HRR by using automatic blood pressure monitor Results: : SBP at rest were significantly decreased in both groups, but these changes were not different between groups. DBP at rest and during exercise was significantly decreased in HIT, but not in CME. However, SBP during exercise was significantly decreased in CME, but not in HIT. EPCs and FMD were significantly increased in HIT, but not in CME. Conclusions: The results of this study suggest that HIT and CME equally have beneficial effects on blood pressure reduction in pre- and hypertensive patients. However, HIT may improve endothelial function better than CME. Therefore, HIT can be an effective rehabilitation programs for hypertensive patients.
FRI0022 Rapid and sustained remission contributes to improved psychosocial outcomes after 1 year of treatment in patients with early rheumatoid arthritis: data from the carera trial
Authors: K. Van der Elst, P. Verschueren, V. Stouten, S. Pazmino, D. De Cock, J. Joly, P. Moons, R. Westhovens
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The goal of early rheumatoid arthritis (RA) treatment is to reach remission as soon as possible, as this initial treatment response is a strong predictor of long-term clinical outcomes. Rapidly reaching remission is not only clinically meaningful, it also matters from the patient's perspective.<sup>1</sup> Yet, the influence of an initial response on patients' future psychosocial functioning remains understudied in early RA. <h3>Objectives</h3> To explore the association between the initial clinical response of patients with early RA and their psychosocial functioning after 1 year of treatment. <h3>Methods</h3> We included patients with early RA (disease duration ≤1 year) who started first-time treatment within the Care in early RA (CareRA) trial.<sup>2</sup> Based on the speed of response defined as the response at week 16, and the stability of response evaluated from week 16 onwards until week 52 of treatment, we created 4 profiles of initial clinical response relevant to patients: persistent responders, secondary failures, delayed responders and non-responders (table 1). Having a response was defined as a disease activity score (DAS28CRP)&lt;2.6 indicating remission. Psychosocial functioning was operationalized using relevant subscales of the Short-form 36 (SF-36) and the Revised Illness Perception Questionnaire (IPQ-R) (table 2). We built multiple linear regression models for each psychosocial outcome separately adjusted for confounding variables. Imputation using the Expectation-Maximisation method was performed for missing SF-36 and IPQ-R scores (range 22.2%&gt;23.1%) only at week 52. <h3>Results</h3> The 333 included patients shared typical characteristics of an early RA population (69.5% being woman, mean(SD) age of 52.3 (13.0) years), with no differences in demographics between patients for the different response profiles. In almost all regression models, the initial clinical response profiles were identified as significant predictors for each psychosocial outcome at week 52 (table 2). A rapid and sustained response, when compared to having a relapse after initial response or a delayed response or no response at all, resulted in higher vitality, less interference with normal social activities, less problems with work or other daily activities because of emotional problems, an improved mental health, more positive beliefs about disease consequences, a higher belief in the effect of treatment, and a more coherent illness understanding. <h3>References</h3> [1] Van der Elst K, et al. Arthritis Care Res (Hoboken)2016;68(9):1278–87. [2] Verschueren P, et al. Ann Rheum Dis. 2017;76(3):511–520. <h3>Disclosure of Interest</h3> None declared
Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia
Authors: Tigran Ghazanchyan, Dickran Kazandjian, Donna Przepiorka, Kelly J. Norsworthy, Emma Scott, Luis Santana-Quintero, Svetlana Petrovskaya, Yong Zhang, Amy Rosenberg, Ashutosh Rao, Richard Pazdur, Ann T. Farrell, Julia A. Beaver, Vahan Simonyan
Journal: Blood (2018)
Abstract 15219: Statin Decision-Making Since the 2013 AHA/ACC Cholesterol Guidelines: Do Clinicians Do What They Say?
Authors: Angela Lowenstern, Shuang Li, Ann Marie Navar, Salim Virani, Michael J Louie, L. Veronica Lee, Eric D Peterson, Tracy Y Wang
Journal: Circulation (2017)

Background: The 2013 ACC/AHA cholesterol guidelines recommend statin treatment based on patients’ predicted atherosclerotic cardiovascular disease (ASCVD) risk instead of low density lipoprotein (LDL) levels. The extent to which these guidelines have been adopted by clinicians and implemented in practice is unknown. Methods: The PALM Registry surveyed clinicians about whether they would prescribe statins for primary prevention in 3 hypothetical scenarios: 1) diabetes; 2) high ASCVD risk (>7.5%) with high cholesterol (LDL≥130 mg/dL); or 3) low ASCVD risk (<7.5%) with high cholesterol (LDL 130-189 mg/dL). We examined agreement between survey responses and observed statin use rates in the 2,327 PALM Registry patients with similar conditions. Logistic regression assessed whether clinicians who would treat in the hypothetical scenario were more likely to treat in actual practice. Results: Among 774 surveyed clinicians, 84.5% reported they were likely to prescribe a statin to a diabetic patient, 92.9% to a high...
THU0389 Borderline pulmonary hypertension was associated with reduced cardiac output during exercise in patients with connective tissue diseases
Authors: A. Marra, C. Nagel, B. Egenlauf, P. Xanthouli, S. Harutyunova, N. Blank, H.-M. Lorenz, C. Fiehn, N. Benjamin, C. Fischer, E. Bossone, A. Cittadini, E. Grünig
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In patients with systemic sclerosis (SSc) borderline mean pulmonary arterial pressures (mPAP; 21–24 mmHg at rest) are a frequent finding and could represent an intermediate stage between normal pulmonary pressures and manifest pulmonary hypertension (PH).<sup>1</sup>. <h3>Objectives</h3> The objective of this prospective study was to compare right ventricular function and pulmonary arterial compliance (PAC) at rest and during exercise between systemic sclerosis (SSc)-patients with normal and borderline mean pulmonary artery pressures, respectively. <h3>Methods</h3> SSc-patients (n=112) underwent clinical assessment. including right heart catheterization at rest and during exercise and were divided in three groups according to their resting mPAP values: normal mPAP (≤20 mmHg), borderline mPAP (21–24 mmHg) and manifest pulmonary hypertension (PH, mPAP ≥25 mmHg). Results were compared between groups by ANOVA followed by post-hoc student's t-test. <h3>Results</h3> SSc Patients with borderline PAP showed significantly lower cardiac index (CI) increase during exercise and higher PVR values than SSc patients with normal PAP at rest. Six-Minute-walking distance (6MWD) and PAC (stroke volume/(systolicPAP-diastolicPAP) were significantly lower in the borderline PAP group compared to patients with normal PAP. <h3>Conclusions</h3> The results of this study suggest that impaired 6MWD in SSc-patients with borderline PAP (and normal RV function at rest) might be caused by reduced RV contractile reserve (reduced RV output) and reduced PAC during exercise rather than by elevated pressures in the borderline range alone. These findings give further evidence for borderline PAP being an early stage of pulmonary vascular disease. <h3>Reference</h3> [1] Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther. 2014Dec 10;16(6):493. <h3>Acknowledgements</h3> Special thanks to the patients that participated in this research. <h3>Disclosure of Interest</h3> None declared
Metabolic (Bariatric and Nonbariatric) Surgery for Type 2 Diabetes: A Personal Perspective Review
Authors: Henry Buchwald, Jane N. Buchwald
Journal: Diabetes Care (2019)

Metabolic surgery can cause amelioration, resolution, and possible cure of type 2 diabetes. Bariatric surgery is metabolic surgery. In the future, there will be metabolic surgery operations to treat type 2 diabetes that are not focused on weight loss. These procedures will rely on neurohormonal modulation related to the gut as well as outside the peritoneal cavity. Metabolic procedures are and will always be in flux as surgeons seek the safest and most effective operative modality; there is no enduring gold standard operation. Metabolic bariatric surgery for type 2 diabetes is more than part of the clinical armamentarium, it is an invitation to perform basic research and to achieve fundamental scientific knowledge.
Development of a Coaxial 3D Printing Platform for Biofabrication of Implantable Islet‐Containing Constructs
Authors: Xiao Liu, Sarah‐Sophia D. Carter, Max Jurie Renes, Juewan Kim, Darling Macarena Rojas‐Canales, Daniella Penko, Cameron Angus, Stephen Beirne, Christopher John Drogemuller, Zhilian Yue, Patrick T. Coates, Gordon G. Wallace
Journal: Advanced Healthcare Materials (2019)

Abstract Over the last two decades, pancreatic islet transplantations have become a promising treatment for Type I diabetes. However, although providing a consistent and sustained exogenous insulin supply, there are a number of limitations hindering the widespread application of this approach. These include the lack of sufficient vasculature and allogeneic immune attacks after transplantation, which both contribute to poor cell survival rates. Here, these issues are addressed using a biofabrication approach. An alginate/gelatin‐based bioink formulation is optimized for islet and islet‐related cell encapsulation and 3D printing. In addition, a custom‐designed coaxial printer is developed for 3D printing of multicellular islet‐containing constructs. In this work, the ability to fabricate 3D constructs with precise control over the distribution of multiple cell types is demonstrated. In addition, it is shown that the viability of pancreatic islets is well maintained after the 3D printing process. Taken together, these results represent the first step toward an improved vehicle for islet transplantation and a potential novel strategy to treat Type I diabetes.
Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models
Authors: Claire Fritz, Scott M. Portwood, Julie Adams, Tara Cronin, Linda Lutgen-Dunckley, Brandon L Martens, Callum M. Sloss, Krystal Watkins, Yelena Kovtun, Sharlene Adams, Eunice S. Wang
Journal: Blood (2018)
FRI0142 The comparison of the ultrasonographic synovial findings between intravenous administration and subcutaneous injection of tocilizumab
Authors: T. Okano, K. Inui, Y. Yamada, K. Mandai, K. Mamoto, Y. Sugioka, M. Tada, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Biologic disease-modifying anti-rheumatic drugs (bDMARDs) that target cytokines and cytokine receptors such as tumour necrosis factor (TNF) alpha and interleukin (IL) 6 have been established as a standard therapy in patients with rheumatoid arthritis (RA). Tocilizumab (TCZ) that targets IL-6 receptors has two administration routes such as intravenous administration (IV) or subcutaneous injection (SC). The effect of TCZ-SC therapy demonstrated comparable efficacy and safety to TCZ-IV therapy in clinical study.<sup>1, 2</sup> However, there have been no reports that evaluate the effect of TCZ-IV and SC for synovitis by imaging modality. <h3>Objectives</h3> The aim of this study was to compare the ultrasound findings between patients with rheumatoid arthritis (RA) treated by TCZ-IV and SC. <h3>Methods</h3> All patients with RA who treated with TCZ in Osaka City University RA registry (1140 patients with RA and 390 patients using bDMARDs) were included in this cross-sectional study. US examination was performed in MCP, PIP, wrist and MTP joints and finger flexor tendon and wrist extensor tendon, by using HI VISION Ascendus (Hitachi Medical Corporation, Japan) with a multifrequency linear transducer (18–6 MHz). The grey scale (GS) and power Doppler (PD) findings were assessed by the semi-quantitative method (0–3). GS score and PD score (both 0–156 points) were defined as the sum total of each score. <h3>Results</h3> We analysed total 76 patients who treated TCZ, 27 patients in IV group and 49 patients in SC group (mean age: 62.9±14.0 vs 66.0±13.2 years, p=0.343, mean duration of RA: 17.1±11.1 vs 13.7±12.3 years, p=0.218). The duration of TCZ use was significantly longer in IV (4.6±2.2 vs 3.0±2.4 years, p=0.004). Clinically, DAS28-ESR improved from 5.3±1.5 at baseline to 2.4±1.1 at US examination in IV group, and it improved from 5.2±1.4 to 2.8±1.5 in SC group. US findings were not significantly differenced in both groups, GS score: 11.7±12.5 vs 10.9±9.6 (p=0.751), PD score: 5.3±8.1 vs 5.7±6.8 (p=0.832), max PD grade: 1.3±0.9 vs 1.4±0.9 (p=0.571) in IV and SC respectively. <h3>Conclusions</h3> We compared the ultrasound findings between patients with RA treated by TCZ-IV and SC. Ultrasound findings between IV and SC were not significantly differenced. Both administration routes of TCZ are effective for the treatment in patients with RA. <h3>References</h3> [1] Ogata A, Tanimura K, Sugimoto T, et al. Arthritis Care Res. 2014;66:344–54. [2] Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Ann Rheum Dis. 2014;73:69–74. <h3>Acknowledgements</h3> We wish to thank Tomoko Nakatsuka for clinical assistant, Setsuko Takeda, Emi Yamashita and Yuko Yoshida for their special efforts as a sonographer and collecting data. <h3>Disclosure of Interest</h3> None declared
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
Authors: Suzanne Lentzsch, Hang Quach, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, Pieter Sonneveld, Jordan Schecter, Vania T M Hungria
Journal: Blood (2017)